P21-aktivált kináz gátlók vizsgálata "in silico" módszerek felhasználásával

Translated title of the contribution: Development of PAK1 kinase inhibitors with "in silico" modeling methods

Baska Ferenc, Szántai Kis Csaba, Greff Zoltán, Marosfalvi Jeno, Z. Varga, G. Kéri, L. Őrfi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The important role of several protein kinases in many diseases has been well documented. Nowadays they are known as an important class of drug targets. The similarity of the structures of the protein kinases makes the development of selective inhibitors difficult. Only a few selective PAK1 kinase inhibitors have been published in the literature, so we have applied "in silico" methods to aid the development of further selective PAK1 inhibitors. The effects of the potential inhibitors were screened in biochemical assays and pharmacologycal features have been determined for further development.

Original languageHungarian
Pages (from-to)155-161
Number of pages7
JournalActa Pharmaceutica Hungarica
Volume80
Issue number4
Publication statusPublished - 2010

Fingerprint

p21-Activated Kinases
Computer Simulation
Protein Kinases
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

P21-aktivált kináz gátlók vizsgálata "in silico" módszerek felhasználásával. / Ferenc, Baska; Csaba, Szántai Kis; Zoltán, Greff; Jeno, Marosfalvi; Varga, Z.; Kéri, G.; Őrfi, L.

In: Acta Pharmaceutica Hungarica, Vol. 80, No. 4, 2010, p. 155-161.

Research output: Contribution to journalArticle

Ferenc, Baska ; Csaba, Szántai Kis ; Zoltán, Greff ; Jeno, Marosfalvi ; Varga, Z. ; Kéri, G. ; Őrfi, L. / P21-aktivált kináz gátlók vizsgálata "in silico" módszerek felhasználásával. In: Acta Pharmaceutica Hungarica. 2010 ; Vol. 80, No. 4. pp. 155-161.
@article{1d8331e2ca8c4ab8bb73ee6b910e8e10,
title = "P21-aktiv{\'a}lt kin{\'a}z g{\'a}tl{\'o}k vizsg{\'a}lata {"}in silico{"} m{\'o}dszerek felhaszn{\'a}l{\'a}s{\'a}val",
abstract = "The important role of several protein kinases in many diseases has been well documented. Nowadays they are known as an important class of drug targets. The similarity of the structures of the protein kinases makes the development of selective inhibitors difficult. Only a few selective PAK1 kinase inhibitors have been published in the literature, so we have applied {"}in silico{"} methods to aid the development of further selective PAK1 inhibitors. The effects of the potential inhibitors were screened in biochemical assays and pharmacologycal features have been determined for further development.",
keywords = "Kinase assay, Molecular modeling, PAK1 kinase, Schr{\"o}dinger suite",
author = "Baska Ferenc and Csaba, {Sz{\'a}ntai Kis} and Greff Zolt{\'a}n and Marosfalvi Jeno and Z. Varga and G. K{\'e}ri and L. Őrfi",
year = "2010",
language = "Hungarian",
volume = "80",
pages = "155--161",
journal = "Acta Pharmaceutica Hungarica",
issn = "0001-6659",
publisher = "Magyar Gyogyszereszeti Tarsasag",
number = "4",

}

TY - JOUR

T1 - P21-aktivált kináz gátlók vizsgálata "in silico" módszerek felhasználásával

AU - Ferenc, Baska

AU - Csaba, Szántai Kis

AU - Zoltán, Greff

AU - Jeno, Marosfalvi

AU - Varga, Z.

AU - Kéri, G.

AU - Őrfi, L.

PY - 2010

Y1 - 2010

N2 - The important role of several protein kinases in many diseases has been well documented. Nowadays they are known as an important class of drug targets. The similarity of the structures of the protein kinases makes the development of selective inhibitors difficult. Only a few selective PAK1 kinase inhibitors have been published in the literature, so we have applied "in silico" methods to aid the development of further selective PAK1 inhibitors. The effects of the potential inhibitors were screened in biochemical assays and pharmacologycal features have been determined for further development.

AB - The important role of several protein kinases in many diseases has been well documented. Nowadays they are known as an important class of drug targets. The similarity of the structures of the protein kinases makes the development of selective inhibitors difficult. Only a few selective PAK1 kinase inhibitors have been published in the literature, so we have applied "in silico" methods to aid the development of further selective PAK1 inhibitors. The effects of the potential inhibitors were screened in biochemical assays and pharmacologycal features have been determined for further development.

KW - Kinase assay

KW - Molecular modeling

KW - PAK1 kinase

KW - Schrödinger suite

UR - http://www.scopus.com/inward/record.url?scp=79251487213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251487213&partnerID=8YFLogxK

M3 - Article

C2 - 21404476

AN - SCOPUS:79251487213

VL - 80

SP - 155

EP - 161

JO - Acta Pharmaceutica Hungarica

JF - Acta Pharmaceutica Hungarica

SN - 0001-6659

IS - 4

ER -